Cargando…
Potential Cost-Effectiveness of RSV Vaccination of Infants and Pregnant Women in Turkey: An Illustration Based on Bursa Data
BACKGROUND: Worldwide, respiratory syncytial virus (RSV) is considered to be the most important viral cause of respiratory morbidity and mortality among infants and young children. Although no active vaccine is available on the market yet, there are several active vaccine development programs in var...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045176/ https://www.ncbi.nlm.nih.gov/pubmed/27689356 http://dx.doi.org/10.1371/journal.pone.0163567 |
_version_ | 1782457071061434368 |
---|---|
author | Pouwels, Koen B. Bozdemir, Sefika E. Yegenoglu, Selen Celebi, Solmaz McIntosh, E. David Unal, Serhat Postma, Maarten J. Hacimustafaoglu, Mustafa |
author_facet | Pouwels, Koen B. Bozdemir, Sefika E. Yegenoglu, Selen Celebi, Solmaz McIntosh, E. David Unal, Serhat Postma, Maarten J. Hacimustafaoglu, Mustafa |
author_sort | Pouwels, Koen B. |
collection | PubMed |
description | BACKGROUND: Worldwide, respiratory syncytial virus (RSV) is considered to be the most important viral cause of respiratory morbidity and mortality among infants and young children. Although no active vaccine is available on the market yet, there are several active vaccine development programs in various stages. To assess whether one of these vaccines might be a future asset for national immunization programs, modeling the costs and benefits of various vaccination strategies is needed. OBJECTIVES: To evaluate the potential cost-effectiveness of RSV vaccination of infants and/or pregnant women in Turkey. METHODS: A multi-cohort static Markov model with cycles of one month was used to compare the cost-effectiveness of vaccinated cohorts versus non-vaccinated cohorts. The 2014 Turkish birth cohort was divided by twelve to construct twelve monthly birth cohorts of equal size (111,459 new-borns). Model input was based on clinical data from a multicenter prospective study from Bursa, Turkey, combined with figures from the (inter)national literature and publicly available data from the Turkish Statistical Institute (TÜÏK). Incremental cost-effectiveness ratios (ICERs) were expressed in Turkish Lira (TL) per quality-adjusted life year (QALY) gained. RESULTS: Vaccinating infants at 2 and 4 months of age would prevent 145,802 GP visits, 8,201 hospitalizations and 48 deaths during the first year of life, corresponding to a total gain of 1650 QALYs. The discounted ICER was estimated at 51,969 TL (26,220 US $ in 2013) per QALY gained. Vaccinating both pregnant women and infants would prevent more cases, but was less attractive from a pure economic point of view with a discounted ICER of 61,653 TL (31,106 US $ in 2013) per QALY. Vaccinating only during pregnancy would result in fewer cases prevented than infant vaccination and a less favorable ICER. CONCLUSION: RSV vaccination of infants and/or pregnant women has the potential to be cost-effective in Turkey. Although using relatively conservative assumptions, all evaluated strategies remained slightly below the threshold of 3 times the GDP per capita. |
format | Online Article Text |
id | pubmed-5045176 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-50451762016-10-27 Potential Cost-Effectiveness of RSV Vaccination of Infants and Pregnant Women in Turkey: An Illustration Based on Bursa Data Pouwels, Koen B. Bozdemir, Sefika E. Yegenoglu, Selen Celebi, Solmaz McIntosh, E. David Unal, Serhat Postma, Maarten J. Hacimustafaoglu, Mustafa PLoS One Research Article BACKGROUND: Worldwide, respiratory syncytial virus (RSV) is considered to be the most important viral cause of respiratory morbidity and mortality among infants and young children. Although no active vaccine is available on the market yet, there are several active vaccine development programs in various stages. To assess whether one of these vaccines might be a future asset for national immunization programs, modeling the costs and benefits of various vaccination strategies is needed. OBJECTIVES: To evaluate the potential cost-effectiveness of RSV vaccination of infants and/or pregnant women in Turkey. METHODS: A multi-cohort static Markov model with cycles of one month was used to compare the cost-effectiveness of vaccinated cohorts versus non-vaccinated cohorts. The 2014 Turkish birth cohort was divided by twelve to construct twelve monthly birth cohorts of equal size (111,459 new-borns). Model input was based on clinical data from a multicenter prospective study from Bursa, Turkey, combined with figures from the (inter)national literature and publicly available data from the Turkish Statistical Institute (TÜÏK). Incremental cost-effectiveness ratios (ICERs) were expressed in Turkish Lira (TL) per quality-adjusted life year (QALY) gained. RESULTS: Vaccinating infants at 2 and 4 months of age would prevent 145,802 GP visits, 8,201 hospitalizations and 48 deaths during the first year of life, corresponding to a total gain of 1650 QALYs. The discounted ICER was estimated at 51,969 TL (26,220 US $ in 2013) per QALY gained. Vaccinating both pregnant women and infants would prevent more cases, but was less attractive from a pure economic point of view with a discounted ICER of 61,653 TL (31,106 US $ in 2013) per QALY. Vaccinating only during pregnancy would result in fewer cases prevented than infant vaccination and a less favorable ICER. CONCLUSION: RSV vaccination of infants and/or pregnant women has the potential to be cost-effective in Turkey. Although using relatively conservative assumptions, all evaluated strategies remained slightly below the threshold of 3 times the GDP per capita. Public Library of Science 2016-09-30 /pmc/articles/PMC5045176/ /pubmed/27689356 http://dx.doi.org/10.1371/journal.pone.0163567 Text en © 2016 Pouwels et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Pouwels, Koen B. Bozdemir, Sefika E. Yegenoglu, Selen Celebi, Solmaz McIntosh, E. David Unal, Serhat Postma, Maarten J. Hacimustafaoglu, Mustafa Potential Cost-Effectiveness of RSV Vaccination of Infants and Pregnant Women in Turkey: An Illustration Based on Bursa Data |
title | Potential Cost-Effectiveness of RSV Vaccination of Infants and Pregnant Women in Turkey: An Illustration Based on Bursa Data |
title_full | Potential Cost-Effectiveness of RSV Vaccination of Infants and Pregnant Women in Turkey: An Illustration Based on Bursa Data |
title_fullStr | Potential Cost-Effectiveness of RSV Vaccination of Infants and Pregnant Women in Turkey: An Illustration Based on Bursa Data |
title_full_unstemmed | Potential Cost-Effectiveness of RSV Vaccination of Infants and Pregnant Women in Turkey: An Illustration Based on Bursa Data |
title_short | Potential Cost-Effectiveness of RSV Vaccination of Infants and Pregnant Women in Turkey: An Illustration Based on Bursa Data |
title_sort | potential cost-effectiveness of rsv vaccination of infants and pregnant women in turkey: an illustration based on bursa data |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045176/ https://www.ncbi.nlm.nih.gov/pubmed/27689356 http://dx.doi.org/10.1371/journal.pone.0163567 |
work_keys_str_mv | AT pouwelskoenb potentialcosteffectivenessofrsvvaccinationofinfantsandpregnantwomeninturkeyanillustrationbasedonbursadata AT bozdemirsefikae potentialcosteffectivenessofrsvvaccinationofinfantsandpregnantwomeninturkeyanillustrationbasedonbursadata AT yegenogluselen potentialcosteffectivenessofrsvvaccinationofinfantsandpregnantwomeninturkeyanillustrationbasedonbursadata AT celebisolmaz potentialcosteffectivenessofrsvvaccinationofinfantsandpregnantwomeninturkeyanillustrationbasedonbursadata AT mcintoshedavid potentialcosteffectivenessofrsvvaccinationofinfantsandpregnantwomeninturkeyanillustrationbasedonbursadata AT unalserhat potentialcosteffectivenessofrsvvaccinationofinfantsandpregnantwomeninturkeyanillustrationbasedonbursadata AT postmamaartenj potentialcosteffectivenessofrsvvaccinationofinfantsandpregnantwomeninturkeyanillustrationbasedonbursadata AT hacimustafaoglumustafa potentialcosteffectivenessofrsvvaccinationofinfantsandpregnantwomeninturkeyanillustrationbasedonbursadata |